美国NDC复合药物数据库文件

药品名称：商品名称：药品NDC：报告期内： -格式:2020-5-3
NDC包装id：市场分类：活性成分：持证企业：

美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)

药品名称(分析)

商品名

药品NDC

专利人(分析)

报告期内

活性成分

市场分类

规格(分析)

NDC包装id

fentanyl citrate, bupivacaine hydrochloride

HUMAN COMPOUNDED DRUG

73013-1019

OurPharma LLC

2024-2

FENTANYL CITRATE; BUPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 ug/1 mL; 1.25 mg/1 mL

73013-1019-1

Tropicamide 1%, Cyclopentolate 1%, Phenylephrine 2.5%, Ketorolac 0.4%, Proparacaine 0.1%

HUMAN COMPOUNDED DRUG

71266-8221

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

PHENYLEPHRINE HYDROCHLORIDE; KETOROLAC TROMETHAMINE; TROPICAMIDE; CYCLOPENTOLATE HYDROCHLORIDE; PROPARACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

25 mg/1 mL; 4 mg/1 mL; 10 mg/1 mL; 10 mg/1 mL; 1 mg/1 mL

71266-8221-1

Tropicamide 1%, Cyclopentolate 1%, Phenylephrine 10%, Ketorolac 0.5%

HUMAN COMPOUNDED DRUG

71266-8241

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

PHENYLEPHRINE HYDROCHLORIDE; KETOROLAC TROMETHAMINE; TROPICAMIDE; CYCLOPENTOLATE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL; 10 mg/1 mL

71266-8241-1

Tropicamide 1%, Cyclopentolate 1%, Phenylephrine 10%, Ketorolac 0.5%

HUMAN COMPOUNDED DRUG

71266-8241

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

PHENYLEPHRINE HYDROCHLORIDE; KETOROLAC TROMETHAMINE; TROPICAMIDE; CYCLOPENTOLATE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL; 10 mg/1 mL

71266-8241-5

011313 NIACINAMIDE 4% / TAZAROTENE 0.1%

HUMAN COMPOUNDED DRUG

72934-2318

SKNV

2024-2

NIACINAMIDE; TAZAROTENE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .1 g/100 mL

72934-2318-2

101013 NIACINAMIDE 4% / TACROLIMUS 0.1%

HUMAN COMPOUNDED DRUG

72934-2366

SKNV

2024-2

TACROLIMUS; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.1 g/100 mL; 4 g/100 mL

72934-2366-2

161021 CALCIPOTRIENE 0.005% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-2395

SKNV

2024-2

NIACINAMIDE; CALCIPOTRIENE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .005 g/100 mL

72934-2395-2

091137 CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05%

HUMAN COMPOUNDED DRUG

72934-4365

SKNV

2024-2

CALCIPOTRIENE; CLOBETASOL PROPIONATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.005 g/100 mL; .05 g/100 mL

72934-4365-3

141010 HYDROQUINONE 4%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL

72934-6371-2

351021 METRONIDAZOLE 1% / MUPIROCIN 2%

HUMAN COMPOUNDED DRUG

72934-5416

SKNV

2024-2

MUPIROCIN; METRONIDAZOLE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 g/100 mL; 1 g/100 mL

72934-5416-2

011054 NIACINAMIDE 4% / SPIRONOLACTONE 5% Gel

HUMAN COMPOUNDED DRUG

72934-1311

SKNV

2024-1

NIACINAMIDE; SPIRONOLACTONE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; 5 g/100 mL

72934-1311-2

011218 NIACINAMIDE 2% / SPIRONOLACTONE 5% / TRETINOIN 0.025% Gel

HUMAN COMPOUNDED DRUG

72934-1314

SKNV

2024-1

TRETINOIN; SPIRONOLACTONE; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.025 g/100 mL; 5 g/100 mL; 2 g/100 mL

72934-1314-2

011312 NIACINAMIDE 4% / TAZAROTENE 0.05%

HUMAN COMPOUNDED DRUG

72934-2317

SKNV

2024-1

TAZAROTENE; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.05 g/100 mL; 4 g/100 mL

72934-2317-2

011554 DAPSONE 8.5% / NIACINAMIDE 4% Cream

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

8.5 g/100 mL; 4 g/100 mL

72934-2323-2

Povidone-Iodine Repak

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

50 mg/1 mL

61141-4538-4

Ropivacaine HCl

HUMAN COMPOUNDED DRUG

61141-1370

Medi-Fare Drug

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

5 mg/1 mL

61141-1370-5

Proparacaine HCl Repak

HUMAN COMPOUNDED DRUG

61141-4536

Medi-Fare Drug

2024-2

PROPARACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

5 mg/1 mL

61141-4536-4

Succinylcholine Chloride

HUMAN COMPOUNDED DRUG

61141-1351

Medi-Fare Drug

2024-2

SUCCINYLCHOLINE CHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

20 mg/1 mL

61141-1351-1

Phenylephrine HCl

HUMAN COMPOUNDED DRUG

61141-1418

Medi-Fare Drug

2024-2

PHENYLEPHRINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 ug/1 mL

61141-1418-1

Fentanyl Citrate Drip

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

61141-1318-1

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：